Denali Therapeutics (DNLI) Retained Earnings (2017 - 2025)
Historic Retained Earnings for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to -$1.9 billion.
- Denali Therapeutics' Retained Earnings fell 3501.85% to -$1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.9 billion, marking a year-over-year decrease of 3501.85%. This contributed to the annual value of -$1.5 billion for FY2024, which is 3787.57% down from last year.
- Latest data reveals that Denali Therapeutics reported Retained Earnings of -$1.9 billion as of Q3 2025, which was down 3501.85% from -$1.8 billion recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Retained Earnings ranged from a high of -$424.5 million in Q1 2021 and a low of -$1.9 billion during Q3 2025
- Over the past 5 years, Denali Therapeutics' median Retained Earnings value was -$996.7 million (recorded in 2023), while the average stood at -$1.1 billion.
- Examining YoY changes over the last 5 years, Denali Therapeutics' Retained Earnings showed a top increase of 1199.59% in 2021 and a maximum decrease of 8198.89% in 2021.
- Denali Therapeutics' Retained Earnings (Quarter) stood at -$645.0 million in 2021, then tumbled by 50.54% to -$971.0 million in 2022, then fell by 14.96% to -$1.1 billion in 2023, then plummeted by 37.88% to -$1.5 billion in 2024, then decreased by 24.95% to -$1.9 billion in 2025.
- Its Retained Earnings was -$1.9 billion in Q3 2025, compared to -$1.8 billion in Q2 2025 and -$1.7 billion in Q1 2025.